Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts

BMC Medicine

Correspondence

Stephen Resch¹  Jane Kim¹  Marc Brisson²  Johannes Berkhof³  Ann Levin⁴  Raymond Hutubessy⁵  Mark Jit⁶  Carol Levin⁷ 

[1] Center for Health Decision Science, Harvard School of Public Health, 718 Huntington Ave, 02130, Boston, MA, USA;Centre de recherche du CHU de Québec, Hôpital Saint-Sacrement, 1050 Chemin Sainte-Foy, G1S 4L8, Québec, Canada;Department of Infectious Disease Epidemiology, Imperial College, London, UK;Department of Epidemiology and Biostatistics, VU University Medical Centre, PO box 7057, 1007, Amsterdam, MB, The Netherlands;Independent Consultant, 6414 Hollins Dr., 20817, Bethesda, MD, USA;Initiative for Vaccine Research, World Health Organization, 20 Avenue Appia, CH-1211, Geneva, Switzerland;Modelling and Economics Unit, Health Protection Agency, 61 Colindale Avenue, NW9 5EQ, London, UK;Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, UK;PATH, 2201 Westlake Avenue, Suite 200, 98121, Seattle, WA, USA;

关键词: Human papillomavirus;    vaccination;    low- and middle-income countries;    economic evaluation.;   

DOI  :  10.1186/1741-7015-11-23

 received in 2012-11-02, accepted in 2013-01-30,  发布年份 2013

来源: Springer

【 摘 要 】

Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. Analysts informing policy decisions should address the following questions: 1) Is an economic analysis needed? 2) Should analyses address costs, epidemiological outcomes, or both? 3) If costs are considered, what sort of analysis is needed? 4) If outcomes are considered, what sort of model should be used? 5) How complex should the analysis be? 6) How should uncertainty be captured? 7) How should model results be communicated? Selecting the appropriate analysis is essential to ensure that all the important features of the decision problem are correctly represented, but that the analyses are not more complex than necessary. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries.

【 授权许可】

Unknown   
© Jit et al; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.